AKT1 and B-cell chronic lymphocytic leukemia: The PI3K/AKT pathway was also found to be activated in chronic lymphocytic leukemia (CLL) (63), high-risk myelodysplastic syndrome (MDS) and multiple myeloma (MM) (64–66).